多发性原发性皮肤癌与HIV感染、CD4计数及病毒载量的关联
该队列研究分析455例HIV感染者和1945例HIV未感染者,均来自KPNC计划且1996-2008年间诊断至少1种非黑色素瘤皮肤癌(NMSC)。结果显示,相比未感染者,CD4计数<200 cells/mL的HIV感染者后续NMSC总体风险增加44%,鳞状细胞癌(SCC)风险增加222%,且风险与低CD4计数和高病毒载量呈剂量反应关系。
要点
- HIV感染者CD4<200 cells/mL时后续NMSC风险增加44%,SCC风险增加222%。
- SCC风险与低CD4计数和高病毒载量呈剂量反应关系。
- 建议对HIV感染者特别是低CD4或高病毒载量者针对性监测SCC。
核心结论
- HIV感染者相比未感染者后续新发SCC风险更高,但BCC风险未显示差异。
- SCC风险与低CD4计数和高病毒载量呈剂量反应关系,提示免疫功能障碍可能增加SCC风险。
研究设计与样本
- 队列研究分析455例HIV感染者和1945例HIV未感染者,均为KPNC成员,1996-2008年诊断至少1种NMSC。
- 参与者均为白人非西班牙裔、18岁以上,从首次NMSC诊断进入队列并随访至2008年。
- 使用扩展Cox回归模型,将近期CD4计数和病毒载量作为时变协变量分析。
主要发现
- 中位观察时间4.6年,16.5%(n=390)死亡或失去KPNC成员资格且无后续原发性NMSC。
- HIV感染者相比未感染者更年轻(平均52.5 vs 55.5岁)、男性比例更高(97% vs 92%)、吸烟比例更高(57% vs 45%)、超重/肥胖比例更低(50% vs 61%)。
- 相比未感染者,CD4<200 cells/mL的HIV感染者后续NMSC总体风险增加44%,SCC风险增加222%。
关键数值与推荐
- CD4计数<200 cells/mL的HIV感染者后续NMSC风险增加44%(相比HIV未感染者)。
- CD4计数<200 cells/mL的HIV感染者后续SCC风险增加222%(相比HIV未感染者)。
临床怎么用
- 对HIV感染者,特别是CD4计数低或病毒载量高者,应针对性监测SCC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Persons with human immunodeficiency virus (HIV) have a 2.8-fold higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Individuals with a prior NMSC history are at increased risk for subsequent NMSC, but the magnitude of risk and its relation to HIV disease-related factors, including CD4 count and viral load (VL), are unknown. OBJECTIVE: To better understand how laboratory markers currently used to evaluate HIV disease progression may be associated with subsequent NMSC risk. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed 455 HIV-infected and 1945 HIV-uninfected patients, all of them members of the Kaiser Permanente Northern California (KPNC) health care plan, diagnosed with at least 1 NMSC from 1996-2008 to determine risk of subsequent NMSCs in relation to CD4 count and VL. All participants were white, non-Hispanic persons 18 years or older who had had at least 1 NMSC during the 1996-2008 period. Participants entered the cohort at their first NMSC diagnosis and were observed through 2008. Incidence rates were calculated and adjusted hazard ratios were estimated using extended Cox regression models with recent CD4 count and VL analyzed as time-changing covariates. MAIN OUTCOMES AND MEASURES: Measured CD4 count, VL, and subsequent NMSC (BCC and SCC). RESULTS: The cohort comprised 455 HIV-infected participants (13 [3%] women) and 1952 HIV-uninfected participants (154 [8%] women). Median duration of observation was 4.6 years, and 16.5% (n = 390) either died (n = 35) or lost KPNC membership status (n = 355) without having a subsequent primary NMSC. Compared with HIV-uninfected persons, HIV-infected individuals were slightly younger (mean age, 52.5 vs 55.5 years), more likely men (97% vs 92%), more likely to have smoked (57% vs 45%), and less likely to be overweight/obese (50% vs 61%). The small observed differences by HIV status in matching characteristics (ie, age and sex) resulted from the restriction of the original cohort to those with at least 1 NMSC. Compared with uninfected individuals, those with HIV infection with a recent biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% increased risk of subsequent NMSC overall and a 222% increase risk of SCC in particular, suggesting that subsequent SCC risk is associated with immune dysfunction. CONCLUSIONS AND RELEVANCE: HIV-infected persons compared with HIV-uninfected persons were are at higher risk for subsequent new SCC but not BCC, with a dose-response relationship between risk and lower CD4 counts and higher VLs. Subsequent new primary SCCs had a strong association with lower CD4 and higher VL among HIV-infected persons, suggesting that immune dysfunction might contribute to increased SCC risk. Clinical implications include targeted monitoring for SCC among HIV-infected individuals, particularly those with low CD4 counts or high VLs.
引用
- Asgari MM, Ray GT, Quesenberry CP, et al. Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load. JAMA Dermatol. 2017. PMID: 28700773. doi:10.1001/jamadermatol.2017.1716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。